0.00
—
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Endonovo Therapeutics
From its filings with the US Securities and Exchange Commission
Endonovo Therapeutics is based in Woodland Hills, California and is incorporated in Delaware. Its shares trade on OTC under the ticker ENDV. The SEC classifies its business as electromedical & electrotherapeutic apparatus. In the fiscal year to 31 December 2022, it reported revenue of $135,355 and a net loss of $18.5m. At that date it held total assets of $1.3m and shareholders' equity of −$32.2m. By business, Royalty [Member] brought in 83.9% of revenue, followed by Direct Sales Medical Care Providers Gross [Member] at 16.1%.
Resources International, Inc. began operations on September 1, 2011, and was formally incorporated on October 17, 2011.
December 22, 2017, we acquired intellectual property and other assets (the “RGN Assets”) from Rio Grande Neurosciences, Inc.
Company is negotiating with a major distribution partner in order to initiate the marketing of SofPulse® in South and Central America.
(GDP) of most developed nations, health care can form an enormous part of a country’s economy.
U.S. GDP by 2025. Globally, by 2040, Healthcare spending is expected to exceed $18 Trillion annually.
SofPulse® allows patients to get back to an active life faster with less use of narcotics.
SofPulse® device is manufactured for us by ADM Tronics, Inc. in an FDA approved facility in Northvale, New Jersey.
Quoted from its 10-K, filed 17 Apr 2023. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 9 Mar 2012
- Website
- endonovo.com ↗
- Head office
- 6320 CANOGA AVENUE, WOODLAND HILLS, CA, 91367
- Incorporated in
- DE
- Classification
- Electromedical & Electrotherapeutic Apparatus
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Mr. Ira WeisbergPresident, Chief Commercial Officer - Medical Division
- Alan CollierChief Executive Officer, Interim Chief Financial Officer, Secretary, Director, since 2012$270,617
- Dr. Nevena ZubcevikChief Medical Officer
- Steven BarnesIR Contact Officer
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Endonovo Therapeutics Inc has several strengths that contribute to its competitive advantage:
- Endonovo possesses proprietary technology that sets it apart from competitors in the field.
- The company holds a robust portfolio of patents and trademarks, providing legal protection and opportunities for revenue generation.
- Endonovo is led by a team of industry experts with extensive knowledge and experience in the biotechnology sector.
Weaknesses
- Despite its strengths, Endonovo Therapeutics Inc also faces certain weaknesses:
- The company may struggle with limited funding, which could hinder its ability to pursue growth opportunities and meet financial obligations.
- Endonovo relies heavily on strategic partnerships for research, development, and distribution. Overdependence on these alliances may expose the company to risks associated with partner performance and collaboration.
Opportunities
- Endonovo Therapeutics Inc can leverage the following opportunities to enhance its business:
- With increasing awareness and acceptance of its technology, the company can explore new markets and expand its customer base.
- Forming strategic partnerships and collaborations with renowned institutions, academia, and industry players can provide access to resources, expertise, and increased market reach.
Threats
- Endonovo Therapeutics Inc should be aware of the following threats that could impact its growth:
- The biotechnology sector is highly competitive, with many established players and new entrants. Endonovo must differentiate itself and continuously innovate to stay ahead.
- Changing regulations and compliance requirements in the industry may pose challenges for the company. Staying informed and adapting to these changes is crucial.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.